Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Study aims to improve shared Decision-Making in metastatic breast cancer

NCT ID NCT03248258

Knowledge-focused Sponsor: University of Alabama at Birmingham Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This completed study from the University of Alabama at Birmingham involved 200 women with metastatic or early-stage breast cancer. Researchers conducted interviews and focus groups with patients, nurses, and doctors to understand how treatment decisions are made, including the option to reduce chemotherapy. The goal was to develop an electronic treatment plan that supports shared decision-making, where patients' values and preferences are considered alongside medical advice.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to better communication tools that help patients and doctors make treatment choices together, improving quality of care.
What could go wrong
This is a small, qualitative study that does not test a treatment. The findings may not apply to all patients or settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

200 people

The number who actually took part.

Started

Jun 2017

Finished

Dec 2022

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Metastatic and Early stage Breast Cancer patients receiving care at UAB Hematology/Oncology Kirklin Clinic. Breast Cancer Patient advocates, oncology nurses, navigators, and Oncology Physicians

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patient Criteria (Phase I,II,III): Inclusion Criteria: * 1\. Women with age ≥ 18 * 2\. Presence of Metastatic Breast Cancer or Early Stage Breast Cancer * 3\. Patients may be receiving any line and type of therapy including both standard of care and clinical trials. Exclusion Criteria: * 1\. Patient who are not able to read and/or speak English * 2\. Patients with a life expectancy less than 3 months * 3\. Patients unable to provide informed consent * 4\. Men Patient Advocates (Phase III) Inclusion criteria: 1\. Providers who are self-identified patient advocates working with breast cancer researchers Exclusion criteria: 1. None Sampling: We will conduct interviews with 10-20 patient advocates for phase 3 of this project. Provider (navigator, nurse, physician) (Pjhase I, III) Inclusion criteria: 2. Providers who have direct contact with breast cancer patients Exclusion criteria: 2\. None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for De-escalation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

breast cancer breast carcinoma breast neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

De-escalation Decision making, shared

Contacts and locations

Locations

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35249, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.